<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;ff=20250203213930&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;ff=20250203213930&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 04 Feb 2025 02:39:31 +0000</lastbuilddate>
<pubDate>Mon, 03 Feb 2025 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>A Win for Clinical Evidence: The First Head-to-Head Trial of Interventional Strategies for the Treatment of Pulmonary Embolism</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39899637/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250203213930&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 4;151(5):274-276. doi: 10.1161/CIRCULATIONAHA.124.072972. Epub 2025 Feb 3.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39899637/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250203213930&v=2.18.0.post9+e462414">39899637</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072972>10.1161/CIRCULATIONAHA.124.072972</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39899637</guid>
<pubDate>Mon, 03 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Sunil V Rao</dc:creator>
<dc:creator>J Antonio T Gutierrez</dc:creator>
<dc:date>2025-02-03</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>A Win for Clinical Evidence: The First Head-to-Head Trial of Interventional Strategies for the Treatment of Pulmonary Embolism</dc:title>
<dc:identifier>pmid:39899637</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072972</dc:identifier>
</item>
<item>
<title>Measure Apolipoprotein B If We Believe What We Say About Precision Medicine</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39899636/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250203213930&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 4;151(5):257-259. doi: 10.1161/CIRCULATIONAHA.123.067559. Epub 2025 Feb 3.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39899636/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250203213930&v=2.18.0.post9+e462414">39899636</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067559>10.1161/CIRCULATIONAHA.123.067559</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39899636</guid>
<pubDate>Mon, 03 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Anna Wolska</dc:creator>
<dc:creator>Donald M Lloyd-Jones</dc:creator>
<dc:creator>Alan T Remaley</dc:creator>
<dc:date>2025-02-03</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Measure Apolipoprotein B If We Believe What We Say About Precision Medicine</dc:title>
<dc:identifier>pmid:39899636</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067559</dc:identifier>
</item>
<item>
<title>Letter by Wang and Peng Regarding Article, "Virus-Induced Acute Respiratory Distress Syndrome Causes Cardiomyopathy Through Eliciting Inflammatory Responses in the Heart"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39899635/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250203213930&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 4;151(5):e33-e34. doi: 10.1161/CIRCULATIONAHA.124.069798. Epub 2025 Feb 3.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39899635/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250203213930&v=2.18.0.post9+e462414">39899635</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069798>10.1161/CIRCULATIONAHA.124.069798</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39899635</guid>
<pubDate>Mon, 03 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Xiang Wang</dc:creator>
<dc:creator>Xiaoping Peng</dc:creator>
<dc:date>2025-02-03</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Wang and Peng Regarding Article, "Virus-Induced Acute Respiratory Distress Syndrome Causes Cardiomyopathy Through Eliciting Inflammatory Responses in the Heart"</dc:title>
<dc:identifier>pmid:39899635</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069798</dc:identifier>
</item>
<item>
<title>Measuring Representativeness in Clinical Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39899634/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250203213930&amp;v=2.18.0.post9+e462414
      <description>Representativeness in randomized clinical trials remains a critical concern, affecting the external validity of trial results, equitable access to the risks and benefits of research participation, and public trust in clinical research. Although representative participation by members of groups traditionally underrepresented in clinical trials is just a surrogate for true diversity, equity, inclusion, and belonging in clinical trials, it can be quantified, allowing stakeholders to add empirical...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 4;151(5):318-330. doi: 10.1161/CIRCULATIONAHA.124.070299. Epub 2025 Feb 3.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Representativeness in randomized clinical trials remains a critical concern, affecting the external validity of trial results, equitable access to the risks and benefits of research participation, and public trust in clinical research. Although representative participation by members of groups traditionally underrepresented in clinical trials is just a surrogate for true diversity, equity, inclusion, and belonging in clinical trials, it can be quantified, allowing stakeholders to add empirical rigor to diversity, equity, inclusion, and belonging efforts. Multiple ways to measure representativeness have been proposed, including the participation-to-prevalence ratio, raw participation proportions or numbers for relevant subgroups, and enrollment fraction for relevant subgroups. These methods have strengths and weaknesses and may be appropriate to report in certain circumstances, depending on why stakeholders seek to assess representativeness. Stakeholders-including regulatory agencies, journal editors, clinical trial investigators, and trial sponsors-may use quantitative measures of representativeness to establish trial enrollment standards, monitor equitable participation in ongoing trials, and condition funding or drug or device approval on achieving specific representativeness targets. However, using quantitative measures of representativeness in this way could have unintended consequences, including researchers "gaming" recruitment strategies to meet target numbers, overlooking nuanced variations within communities, and potentially incentivizing problematic and exploitative recruitment strategies. Although no single method of measuring representativeness offers a comprehensive solution for increasing diversity, equity, inclusion, and belonging in all randomized clinical trials, a carefully designed, multifaceted approach to measuring representativeness may provide stakeholders with useful perspectives for measuring progress in increasing the diversity of clinical trial participation. For stakeholders seeking a single number to assess the representativeness of a trial enrolling patients with a disease state with well-delineated demographics, the participation-to-prevalence ratio is ideal; however, for a more nuanced view of representativeness, the combination of enrollment fraction in subgroups of relevance plus a full report of the demographics of patients approached for enrollment may be more appropriate.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39899634/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250203213930&v=2.18.0.post9+e462414">39899634</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070299>10.1161/CIRCULATIONAHA.124.070299</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39899634</guid>
<pubDate>Mon, 03 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Allen Sanyi</dc:creator>
<dc:creator>Samuel Byiringiro</dc:creator>
<dc:creator>Sanaz Dabiri</dc:creator>
<dc:creator>Mireille Jacobson</dc:creator>
<dc:creator>Amanda Boyd</dc:creator>
<dc:creator>Modele O Ogunniyi</dc:creator>
<dc:creator>Alanna A Morris</dc:creator>
<dc:creator>Rachel Kohn</dc:creator>
<dc:creator>Neal W Dickert</dc:creator>
<dc:creator>Meghan B Lane-Fall</dc:creator>
<dc:creator>Eldrin F Lewis</dc:creator>
<dc:creator>Scott D Halpern</dc:creator>
<dc:creator>Alexander C Fanaroff</dc:creator>
<dc:date>2025-02-03</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Measuring Representativeness in Clinical Trials</dc:title>
<dc:identifier>pmid:39899634</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070299</dc:identifier>
</item>
<item>
<title>Risk of Atrial Fibrillation After Hemorrhagic Stroke: A Nationwide Cohort Study With Propensity Score Matching</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39899633/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250203213930&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 4;151(5):331-333. doi: 10.1161/CIRCULATIONAHA.124.070662. Epub 2025 Feb 3.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39899633/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250203213930&v=2.18.0.post9+e462414">39899633</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070662>10.1161/CIRCULATIONAHA.124.070662</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39899633</guid>
<pubDate>Mon, 03 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Jihun Kang</dc:creator>
<dc:creator>Jung Eun Yoo</dc:creator>
<dc:creator>Byeoung-Jun Jeon</dc:creator>
<dc:creator>Sung Il Im</dc:creator>
<dc:creator>Bongseong Kim</dc:creator>
<dc:creator>Won Hyuk Chang</dc:creator>
<dc:creator>Kyungdo Han</dc:creator>
<dc:creator>Dong Wook Shin</dc:creator>
<dc:date>2025-02-03</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Risk of Atrial Fibrillation After Hemorrhagic Stroke: A Nationwide Cohort Study With Propensity Score Matching</dc:title>
<dc:identifier>pmid:39899633</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070662</dc:identifier>
</item>
<item>
<title>Genetically Predicted IL-18 Inhibition and Risk of Cardiovascular Events: A Mendelian Randomization Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39899632/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250203213930&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 4;151(5):334-336. doi: 10.1161/CIRCULATIONAHA.124.072238. Epub 2025 Feb 3.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39899632/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250203213930&v=2.18.0.post9+e462414">39899632</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072238>10.1161/CIRCULATIONAHA.124.072238</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39899632</guid>
<pubDate>Mon, 03 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Stephen O Brennan</dc:creator>
<dc:creator>Peter J Kelly</dc:creator>
<dc:creator>Sarah Gorey</dc:creator>
<dc:creator>Pádraig Synnott</dc:creator>
<dc:creator>Dipender Gill</dc:creator>
<dc:creator>Martin Dichgans</dc:creator>
<dc:creator>Marios K Georgakis</dc:creator>
<dc:creator>Marie-Joe Dib</dc:creator>
<dc:creator>Eloi Gagnon</dc:creator>
<dc:creator>Niall Mahon</dc:creator>
<dc:creator>Gavin J Blake</dc:creator>
<dc:creator>Christina Jern</dc:creator>
<dc:creator>Hugh S Markus</dc:creator>
<dc:creator>William Whiteley</dc:creator>
<dc:creator>John J McCabe</dc:creator>
<dc:date>2025-02-03</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Genetically Predicted IL-18 Inhibition and Risk of Cardiovascular Events: A Mendelian Randomization Study</dc:title>
<dc:identifier>pmid:39899632</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072238</dc:identifier>
</item>
<item>
<title>Response by Grune and Nahrendorf to Letter Regarding Article, "Virus-Induced Acute Respiratory Distress Syndrome Causes Cardiomyopathy Through Eliciting Inflammatory Responses in the Heart"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39899631/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250203213930&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 4;151(5):e35-e36. doi: 10.1161/CIRCULATIONAHA.124.072688. Epub 2025 Feb 3.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39899631/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250203213930&v=2.18.0.post9+e462414">39899631</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072688>10.1161/CIRCULATIONAHA.124.072688</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39899631</guid>
<pubDate>Mon, 03 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Jana Grune</dc:creator>
<dc:creator>Matthias Nahrendorf</dc:creator>
<dc:date>2025-02-03</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Grune and Nahrendorf to Letter Regarding Article, "Virus-Induced Acute Respiratory Distress Syndrome Causes Cardiomyopathy Through Eliciting Inflammatory Responses in the Heart"</dc:title>
<dc:identifier>pmid:39899631</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072688</dc:identifier>
</item>
<item>
<title>Systematic Review, Meta-Analysis, and Population Study to Determine the Biologic Sex Ratio in Dilated Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39895490/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250203213930&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study demonstrates that DCM is twice as prevalent in male patients. This was partially mitigated by implementing sex-specific DCM diagnostic criteria. The persistent male excess in genotype-positive patients with an equally prevalent genetic risk suggests additional genetic or environmental drivers for sex-biased penetrance.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 3. doi: 10.1161/CIRCULATIONAHA.124.070872. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Dilated cardiomyopathy (DCM) appears to be diagnosed twice as often in male than in female patients. This could be attributed to underdiagnosis in female patients or sex differences in susceptibility. Up to 30% of cases have an autosomal dominant monogenic cause, where equal sex prevalence would be expected. The aim of this systematic review, meta-analysis, and population study was to assess the sex ratio in patients with DCM, stratified by genetic status, and evaluate whether this is influenced by diagnostic bias.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A literature search identified DCM patient cohorts with discernible sex ratios. Exclusion criteria were studies with a small (n&lt;100), pediatric, or peripartum population. Meta-analysis and metaregression compared the proportion of female participants for an overall DCM cohort and the following subtypes: all genetic DCM, individual selected DCM genes (<i>TTN</i> and <i>LMNA</i>), and gene-elusive DCM. Population DCM sex ratios generated from diagnostic codes were also compared with those from sex-specific means using the UK Biobank imaging cohort; this established International Classification of Diseases, 10th revision-coded, novel imaging-first, and genotype-first-determined sex ratios.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 99 studies, with 37 525 participants, were included. The overall DCM cohort had a 0.30 female proportion (95% CI, 0.28-0.32), corresponding to a male:female ratio (M:F) of 2.38:1. This was similar to patients with an identified DCM variant (0.31 [95% CI, 0.26-0.36]; M:F 2.22:1; <i>P</i>=0.56). There was also no significant difference when compared with patients with gene-elusive DCM (0.30 [95% CI, 0.24-0.37]; M:F 2.29:1; <i>P</i>=0.81). Furthermore, the ratio within autosomal dominant gene variants was not significantly different for <i>TTN</i> (0.28 [95% CI, 0.22-0.36]; M:F 2.51:1; <i>P</i>=0.82) or <i>LMNA</i> (0.35 [95% CI, 0.27-0.44]; M:F 1.84:1; <i>P</i>=0.41). Overall, the sex ratio for DCM in people with disease attributed to autosomal dominant gene variants was similar to the all-cause group (0.34 [95% CI, 0.28-0.40]; M:F 1.98:1; <i>P</i>=0.19). In the UK Biobank (n=47 549), DCM defined by International Classification of Diseases, 10th revision, coding had 4.5:1 M:F. However, implementing sex-specific imaging-first and genotype-first diagnostic approaches changed this to 1.7:1 and 2.3:1, respectively.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study demonstrates that DCM is twice as prevalent in male patients. This was partially mitigated by implementing sex-specific DCM diagnostic criteria. The persistent male excess in genotype-positive patients with an equally prevalent genetic risk suggests additional genetic or environmental drivers for sex-biased penetrance.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.crd.york.ac.uk/prospero; Unique identifier: CRD42023451944.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39895490/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250203213930&v=2.18.0.post9+e462414">39895490</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070872>10.1161/CIRCULATIONAHA.124.070872</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39895490</guid>
<pubDate>Mon, 03 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Natalie Bergan</dc:creator>
<dc:creator>Ishika Prachee</dc:creator>
<dc:creator>Lara Curran</dc:creator>
<dc:creator>Kathryn A McGurk</dc:creator>
<dc:creator>Chang Lu</dc:creator>
<dc:creator>Antonio de Marvao</dc:creator>
<dc:creator>Wenjia Bai</dc:creator>
<dc:creator>Brian P Halliday</dc:creator>
<dc:creator>John Gregson</dc:creator>
<dc:creator>Declan P O'Regan</dc:creator>
<dc:creator>James S Ware</dc:creator>
<dc:creator>Upasana Tayal</dc:creator>
<dc:date>2025-02-03</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Systematic Review, Meta-Analysis, and Population Study to Determine the Biologic Sex Ratio in Dilated Cardiomyopathy</dc:title>
<dc:identifier>pmid:39895490</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070872</dc:identifier>
</item>
<item>
<title>Focus on the extreme of the spectrum: myocardial infarction with no obstructive coronary arteries and ischaemic cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39895466/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250203213930&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 3;46(5):399-403. doi: 10.1093/eurheartj/ehae891.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39895466/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250203213930&v=2.18.0.post9+e462414">39895466</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae891>10.1093/eurheartj/ehae891</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39895466</guid>
<pubDate>Mon, 03 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2025-02-03</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Focus on the extreme of the spectrum: myocardial infarction with no obstructive coronary arteries and ischaemic cardiomyopathy</dc:title>
<dc:identifier>pmid:39895466</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae891</dc:identifier>
</item>
<item>
<title>Empowering the Profession: The ACC's Commitment to Cutting-Edge Clinical Guidance</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39895434/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250203213930&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 24:S0735-1097(25)00133-0. doi: 10.1016/j.jacc.2025.01.006. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39895434/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250203213930&v=2.18.0.post9+e462414">39895434</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.006>10.1016/j.jacc.2025.01.006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39895434</guid>
<pubDate>Mon, 03 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Cathleen Biga</dc:creator>
<dc:creator>Ana Barac</dc:creator>
<dc:creator>Nicole Bhave</dc:creator>
<dc:date>2025-02-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Empowering the Profession: The ACC's Commitment to Cutting-Edge Clinical Guidance</dc:title>
<dc:identifier>pmid:39895434</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.006</dc:identifier>
</item>
<item>
<title>Bulgarian Society of Cardiology: 50 years on</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39895398/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250203213930&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 3:ehae916. doi: 10.1093/eurheartj/ehae916. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39895398/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250203213930&v=2.18.0.post9+e462414">39895398</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae916>10.1093/eurheartj/ehae916</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39895398</guid>
<pubDate>Mon, 03 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Vassil Traykov</dc:creator>
<dc:creator>Kiril Karamfiloff</dc:creator>
<dc:creator>Assen Goudev</dc:creator>
<dc:date>2025-02-03</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Bulgarian Society of Cardiology: 50 years on</dc:title>
<dc:identifier>pmid:39895398</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae916</dc:identifier>
</item>
<item>
<title>Leaders in cardiology: Julie De Backer</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39895379/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250203213930&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 3:ehae884. doi: 10.1093/eurheartj/ehae884. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39895379/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250203213930&v=2.18.0.post9+e462414">39895379</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae884>10.1093/eurheartj/ehae884</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39895379</guid>
<pubDate>Mon, 03 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Judith Ozkan</dc:creator>
<dc:date>2025-02-03</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Leaders in cardiology: Julie De Backer</dc:title>
<dc:identifier>pmid:39895379</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae884</dc:identifier>
</item>
<item>
<title>Asymptomatic atrial fibrillation: the tasks ahead</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39895147/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250203213930&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 3:ehae835. doi: 10.1093/eurheartj/ehae835. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39895147/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250203213930&v=2.18.0.post9+e462414">39895147</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae835>10.1093/eurheartj/ehae835</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39895147</guid>
<pubDate>Mon, 03 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Marc Lemoine</dc:creator>
<dc:creator>Laura Rottner</dc:creator>
<dc:creator>Paulus Kirchhof</dc:creator>
<dc:date>2025-02-03</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Asymptomatic atrial fibrillation: the tasks ahead</dc:title>
<dc:identifier>pmid:39895147</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae835</dc:identifier>
</item>
<item>
<title>Hospitalization for cardiovascular disease in the year after delivery of twin pregnancies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39894055/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250203213930&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Compared with singletons without HDP, twin pregnancies, even in the absence of HDP, are associated with increased risks for CVD complications in the first year post-partum. These findings highlight the increased strain twin pregnancies place on the maternal cardiovascular system. These findings advocate the need for appropriate pre-conception counselling for those with cardiovascular risk factors undergoing infertility treatment, which increase the risks of multi-foetal gestation,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 3:ehaf003. doi: 10.1093/eurheartj/ehaf003. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Increased cardiovascular demand in twin pregnancies, even those without hypertensive disease of pregnancy (HDP), may pose a greater risk for cardiovascular complications compared with singletons. In this study, the risk of cardiovascular disease (CVD)-related hospitalizations and mortality within the year following delivery in relation to HDP was compared between twin and singleton pregnancies.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using the Nationwide Readmissions Database of US hospitals from 2010 to 2020, the rates of CVD readmission in four exposure groups (twin deliveries with and without HDP and singleton deliveries with and without HDP) were estimated. Cox proportional hazard regression models were used to determine associations with singletons without HDP as the reference.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 36 million delivery hospitalizations, the rates of CVD readmission in twin and singleton pregnancies were 1105.4 and 734.1 per 100 000 delivery admissions, respectively. Compared with singletons without HDP, the adjusted hazard ratio (HR) of CVD readmission was highest for twins with HDP [HR 8.21, 95% confidence interval (CI) 7.48-9.01], followed by singletons with HDP (HR 5.89, 95% CI 5.70-6.08) and then twins without HDP (HR 1.95, 95% CI 1.75, 2.17).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Compared with singletons without HDP, twin pregnancies, even in the absence of HDP, are associated with increased risks for CVD complications in the first year post-partum. These findings highlight the increased strain twin pregnancies place on the maternal cardiovascular system. These findings advocate the need for appropriate pre-conception counselling for those with cardiovascular risk factors undergoing infertility treatment, which increase the risks of multi-foetal gestation, and increased post-partum surveillance in twin pregnancies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39894055/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250203213930&v=2.18.0.post9+e462414">39894055</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf003>10.1093/eurheartj/ehaf003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39894055</guid>
<pubDate>Sun, 02 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Ruby Lin</dc:creator>
<dc:creator>Jessica C Fields</dc:creator>
<dc:creator>Rachel Lee</dc:creator>
<dc:creator>Emily B Rosenfeld</dc:creator>
<dc:creator>Emily E Daggett</dc:creator>
<dc:creator>Ruchira Sharma</dc:creator>
<dc:creator>Cande V Ananth</dc:creator>
<dc:date>2025-02-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Hospitalization for cardiovascular disease in the year after delivery of twin pregnancies</dc:title>
<dc:identifier>pmid:39894055</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf003</dc:identifier>
</item>
<item>
<title>Double double, future trouble? Opportunities for cardio-obstetric collaboration to reduce future cardiovascular events following twin pregnancies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39894054/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250203213930&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 3:ehaf064. doi: 10.1093/eurheartj/ehaf064. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39894054/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250203213930&v=2.18.0.post9+e462414">39894054</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf064>10.1093/eurheartj/ehaf064</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39894054</guid>
<pubDate>Sun, 02 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Alexandria F Williams</dc:creator>
<dc:creator>Anne Marie Valente</dc:creator>
<dc:creator>Katherine E Economy</dc:creator>
<dc:date>2025-02-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Double double, future trouble? Opportunities for cardio-obstetric collaboration to reduce future cardiovascular events following twin pregnancies</dc:title>
<dc:identifier>pmid:39894054</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf064</dc:identifier>
</item>
<item>
<title>Long-term imaging of individual ribosomes reveals ribosome cooperativity in mRNA translation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39892379/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250203213930&amp;v=2.18.0.post9+e462414
      <description>The genetic information stored in mRNAs is decoded by ribosomes during mRNA translation. mRNAs are typically translated by multiple ribosomes simultaneously, but it is unclear whether and how the activity of different ribosomes on an mRNA is coordinated. Here, we develop an imaging approach based on stopless-ORF circular RNAs (socRNAs) to monitor translation of individual ribosomes in either monosomes or polysomes with very high resolution. Using experiments and simulations, we find that...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Jan 23:S0092-8674(25)00045-5. doi: 10.1016/j.cell.2025.01.016. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The genetic information stored in mRNAs is decoded by ribosomes during mRNA translation. mRNAs are typically translated by multiple ribosomes simultaneously, but it is unclear whether and how the activity of different ribosomes on an mRNA is coordinated. Here, we develop an imaging approach based on stopless-ORF circular RNAs (socRNAs) to monitor translation of individual ribosomes in either monosomes or polysomes with very high resolution. Using experiments and simulations, we find that translating ribosomes frequently undergo transient collisions. However, unlike persistent collisions, such transient collisions escape detection by cellular quality control pathways. Rather, transient ribosome collisions promote productive translation by reducing ribosome pausing on problematic sequences, a process we term ribosome cooperativity. Ribosome cooperativity also reduces recycling of ribosomes by quality control pathways, thus enhancing processive translation. Together, our single-ribosome imaging approach reveals that ribosomes cooperate during translation to ensure fast and efficient translation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39892379/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250203213930&v=2.18.0.post9+e462414">39892379</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.016>10.1016/j.cell.2025.01.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39892379</guid>
<pubDate>Sat, 01 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Maximilian F Madern</dc:creator>
<dc:creator>Sora Yang</dc:creator>
<dc:creator>Olivier Witteveen</dc:creator>
<dc:creator>Hendrika A Segeren</dc:creator>
<dc:creator>Marianne Bauer</dc:creator>
<dc:creator>Marvin E Tanenbaum</dc:creator>
<dc:date>2025-02-01</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Long-term imaging of individual ribosomes reveals ribosome cooperativity in mRNA translation</dc:title>
<dc:identifier>pmid:39892379</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.016</dc:identifier>
</item>
<item>
<title>Early fusion intermediate of ACE2-using coronavirus spike acting as an antiviral target</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39889696/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250203213930&amp;v=2.18.0.post9+e462414
      <description>Coronavirus fusion with and entry into the host cell depends on viral spike, which acts as a crucial component of viral infection. However, the lack of receptor-activated spike intermediate conformation has hindered a comprehensive understanding of spike-induced membrane fusion. Here, we captured an angiotensin-converting enzyme 2 (ACE2)-induced early fusion intermediate conformation (E-FIC) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike in which heptad repeat 1 (HR1) in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Jan 24:S0092-8674(25)00041-8. doi: 10.1016/j.cell.2025.01.012. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Coronavirus fusion with and entry into the host cell depends on viral spike, which acts as a crucial component of viral infection. However, the lack of receptor-activated spike intermediate conformation has hindered a comprehensive understanding of spike-induced membrane fusion. Here, we captured an angiotensin-converting enzyme 2 (ACE2)-induced early fusion intermediate conformation (E-FIC) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike in which heptad repeat 1 (HR1) in S2 has ejected while S1 remains attached. This E-FIC can transition to the late FIC after S2' cleavage. Leveraging this discovery, we designed an E-FIC-targeted dual-functional antiviral protein, AL5E. AL5E effectively inactivated ACE2-using coronaviruses and inhibited their infection, outperforming a mono-functional antiviral in protecting animals against these coronaviruses. This study has identified the E-FIC and used it as a target for the development of a dual-functional antiviral for the prevention and treatment of ACE2-using coronavirus infection.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39889696/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250203213930&v=2.18.0.post9+e462414">39889696</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.012>10.1016/j.cell.2025.01.012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39889696</guid>
<pubDate>Fri, 31 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Lixiao Xing</dc:creator>
<dc:creator>Zhimin Liu</dc:creator>
<dc:creator>Xinling Wang</dc:creator>
<dc:creator>Qianying Liu</dc:creator>
<dc:creator>Wei Xu</dc:creator>
<dc:creator>Qiyu Mao</dc:creator>
<dc:creator>Xiang Zhang</dc:creator>
<dc:creator>Aihua Hao</dc:creator>
<dc:creator>Shuai Xia</dc:creator>
<dc:creator>Zezhong Liu</dc:creator>
<dc:creator>Lujia Sun</dc:creator>
<dc:creator>Guangxu Zhang</dc:creator>
<dc:creator>Qian Wang</dc:creator>
<dc:creator>Zhenguo Chen</dc:creator>
<dc:creator>Shibo Jiang</dc:creator>
<dc:creator>Lei Sun</dc:creator>
<dc:creator>Lu Lu</dc:creator>
<dc:date>2025-01-31</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Early fusion intermediate of ACE2-using coronavirus spike acting as an antiviral target</dc:title>
<dc:identifier>pmid:39889696</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.012</dc:identifier>
</item>
<item>
<title>Resolving the three-dimensional interactome of human accelerated regions during human and chimpanzee neurodevelopment</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39889695/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250203213930&amp;v=2.18.0.post9+e462414
      <description>Human accelerated regions (HARs) have been implicated in human brain evolution. However, insight into the genes and pathways they control is lacking, hindering the understanding of their function. Here, we identify 2,963 conserved gene targets for 1,590 HARs and their orthologs in human and chimpanzee neural stem cells (NSCs). Conserved gene targets are enriched for neurodevelopmental functions and are overrepresented among differentially expressed genes (DEGs) identified in human NSCs (hNSCs)...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Jan 24:S0092-8674(25)00036-4. doi: 10.1016/j.cell.2025.01.007. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Human accelerated regions (HARs) have been implicated in human brain evolution. However, insight into the genes and pathways they control is lacking, hindering the understanding of their function. Here, we identify 2,963 conserved gene targets for 1,590 HARs and their orthologs in human and chimpanzee neural stem cells (NSCs). Conserved gene targets are enriched for neurodevelopmental functions and are overrepresented among differentially expressed genes (DEGs) identified in human NSCs (hNSCs) and chimpanzee NSCs (cNSCs) as well as in human versus non-human primate brains. Species-specific gene targets do not converge on any function and are not enriched among DEGs. HAR targets also show cell-type-specific expression in the human fetal brain, including in outer radial glia, which are linked to cortical expansion. Our findings support that HARs influence brain evolution by altering the expression of ancestral gene targets shared between human and chimpanzee rather than by gaining new targets in human and facilitate hypothesis-directed studies of HAR biology.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39889695/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250203213930&v=2.18.0.post9+e462414">39889695</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.007>10.1016/j.cell.2025.01.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39889695</guid>
<pubDate>Fri, 31 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Atreyo Pal</dc:creator>
<dc:creator>Mark A Noble</dc:creator>
<dc:creator>Matheo Morales</dc:creator>
<dc:creator>Richik Pal</dc:creator>
<dc:creator>Marybeth Baumgartner</dc:creator>
<dc:creator>Je Won Yang</dc:creator>
<dc:creator>Kristina M Yim</dc:creator>
<dc:creator>Severin Uebbing</dc:creator>
<dc:creator>James P Noonan</dc:creator>
<dc:date>2025-01-31</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Resolving the three-dimensional interactome of human accelerated regions during human and chimpanzee neurodevelopment</dc:title>
<dc:identifier>pmid:39889695</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.007</dc:identifier>
</item>
<item>
<title>Preservation of Vascular Endothelial Function in Late-Onset Postmenopausal Women</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39886766/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250203213930&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Late-onset menopause is associated with preservation of endothelial function, which is mediated by lower mitoROS-associated oxidative stress. A more favorable profile of circulating lipid metabolites, specifically triglyceride-derived metabolites, contributes to lower endothelial cell mitoROS in late-onset PMW. These findings provide new insight into the possible mechanisms of reduced cardiovascular disease risk in late-onset menopause.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Jan 31. doi: 10.1161/CIRCRESAHA.124.325639. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Postmenopausal women (PMW) who complete menopause at a late age (55+ years) have lower cardiovascular disease risk than PMW who complete menopause at a normal age (45-54 years). However, the influence of late-onset menopause on vascular endothelial dysfunction is unknown. Moreover, the mechanisms by which a later age at menopause may modulate endothelial function remain to be determined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We measured endothelial function (brachial artery flow-mediated dilation [FMD<sub>BA</sub>]) in age-matched late- and normal-onset PMW and a young premenopausal reference group. We determined mitochondrial reactive oxygen species (mitoROS)-related suppression of endothelial function (change in FMD<sub>BA</sub> with an acute dose of the mitochondria-targeted antioxidant MitoQ; ΔFMD<sub>BA, MTQ</sub>) in PMW. The effects of serum from late- and normal-onset PMW and premenopausal women on mitoROS bioactivity in human aortic endothelial cells in culture were assessed. Metabolomics analyses in combination with serum metabolite level normalization and human aortic endothelial cell serum exposure experiments were performed to identify the circulating factors contributing to the serum effects on endothelial cell mitoROS bioactivity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: FMD<sub>BA</sub> in PMW was lower than in premenopausal women. However, FMD<sub>BA</sub> was >;50% higher in late- versus normal-onset PMW and positively related to age at menopause. ΔFMD<sub>BA, MTQ</sub> was >;50% lower in late- versus normal-onset PMW. Serum from normal-onset PMW but not late-onset PMW induced higher mitoROS bioactivity in human aortic endothelial cells compared with serum from premenopausal women. mitoROS bioactivity was negatively related to FMD<sub>BA</sub> and age at menopause. Seventeen metabolites significantly differed between late- and normal-onset PMW; 15 were lipid specific; 8 were triglyceride derived. TG(16:0) was most strongly correlated with mitoROS bioactivity. Normalization of TG(16:0) concentrations in serum from premenopausal women and late-onset PMW to match serum levels in normal-onset PMW abrogated differences in mitoROS bioactivity in serum-treated human aortic endothelial cells.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Late-onset menopause is associated with preservation of endothelial function, which is mediated by lower mitoROS-associated oxidative stress. A more favorable profile of circulating lipid metabolites, specifically triglyceride-derived metabolites, contributes to lower endothelial cell mitoROS in late-onset PMW. These findings provide new insight into the possible mechanisms of reduced cardiovascular disease risk in late-onset menopause.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39886766/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250203213930&v=2.18.0.post9+e462414">39886766</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325639>10.1161/CIRCRESAHA.124.325639</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39886766</guid>
<pubDate>Fri, 31 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Sanna Darvish</dc:creator>
<dc:creator>Kevin O Murray</dc:creator>
<dc:creator>Katelyn R Ludwig</dc:creator>
<dc:creator>Krisha H Avalani</dc:creator>
<dc:creator>Daniel H Craighead</dc:creator>
<dc:creator>Kaitlin A Freeberg</dc:creator>
<dc:creator>Shaun Bevers</dc:creator>
<dc:creator>Julie A Reisz</dc:creator>
<dc:creator>Angelo D'Alessandro</dc:creator>
<dc:creator>Kerrie L Moreau</dc:creator>
<dc:creator>Douglas R Seals</dc:creator>
<dc:creator>Matthew J Rossman</dc:creator>
<dc:date>2025-01-31</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Preservation of Vascular Endothelial Function in Late-Onset Postmenopausal Women</dc:title>
<dc:identifier>pmid:39886766</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325639</dc:identifier>
</item>
<item>
<title>Long-Term Prognostic Implications of Non-Culprit Lesions in Patients Presenting With an Acute Myocardial Infarction: Is It the Angiographic Stenosis Severity or the Underlying High-Risk Morphology?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39886764/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250203213930&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The long-term prognostic implications of the presence and extent of angiographic obstructive non-culprit lesions in patients with acute myocardial infarction are primarily due to their correlation with the underlying high-risk morphology, which confers an increased risk of recurrent MACEs.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Jan 31. doi: 10.1161/CIRCULATIONAHA.124.071855. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Patients with acute myocardial infarction and angiographically obstructive non-culprit lesions are at high risk for recurrent major adverse cardiac events (MACEs). However, it remains largely unknown whether events are due to stenosis severity or due to the underlying high-risk lesion morphology.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Between January 2017 and December 2021, 1312 patients with acute myocardial infarction underwent optical coherence tomography of all the 3 main epicardial arteries after successful percutaneous coronary intervention. Patients and lesions were categorized according to the presence or absence of (1) 1 or more non-culprit angiographic obstructive stenoses with a visual diameter stenosis of ≥50% and (2) 1 or more lesions with an underlying high-risk morphology defined as an optical coherence tomography thin-cap fibroatheroma (TCFA). Patients were followed for up to 5 years (median 4.1 [interquartile range: 3.0-5.0] years). MACEs comprised cardiac death, non-fatal myocardial infarction, and unplanned coronary revascularization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 492 patients had at least 1 obstructive non-culprit lesion, 352 had a single lesion, and 140 had multiple obstructive non-culprit lesions. The presence and number of angiographic obstructive non-culprit lesions correlated with the proportion and number of optical coherence tomography-derived TCFAs. At the lesion level, the prevalence of TCFA was twice as high in obstructive lesions compared with nonobstructive lesions. Patients with obstructive non-culprit lesions had an increased risk of overall MACEs (17.7% versus 12.8%; hazard ratio, 1.39 [95% CI, 1.02-1.91]) and non-culprit lesion-related MACEs (8.7% versus 3.9%; HR, 2.13 [95% CI, 1.26-3.59). Results were similar when patients were categorized on the basis of the underlying TCFA. A proportionally higher rate of overall and non-culprit lesion-related MACEs was observed as the number of obstructive stenoses or TCFAs in non-culprit segments increased. The lesion-specific HRs for obstructive lesion and TCFA were 2.03 (95% CI, 1.06-3.89) and 2.39 (95% CI, 1.29-4.43), respectively. Optical coherence tomography-derived TCFA, but not angiographic obstructive stenosis, was independently predictive of recurrent MACEs in both patient-level and lesion-level multivariable models in which these 2 characteristics were introduced simultaneously.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The long-term prognostic implications of the presence and extent of angiographic obstructive non-culprit lesions in patients with acute myocardial infarction are primarily due to their correlation with the underlying high-risk morphology, which confers an increased risk of recurrent MACEs.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39886764/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250203213930&v=2.18.0.post9+e462414">39886764</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071855>10.1161/CIRCULATIONAHA.124.071855</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39886764</guid>
<pubDate>Fri, 31 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Jiannan Dai</dc:creator>
<dc:creator>Jiawei Zhao</dc:creator>
<dc:creator>Xueming Xu</dc:creator>
<dc:creator>Yuzhu Chen</dc:creator>
<dc:creator>Sibo Sun</dc:creator>
<dc:creator>Shuang Li</dc:creator>
<dc:creator>Lina Cui</dc:creator>
<dc:creator>Yini Wang</dc:creator>
<dc:creator>Lulu Li</dc:creator>
<dc:creator>Ruirong Guo</dc:creator>
<dc:creator>Dongxu Huang</dc:creator>
<dc:creator>Xianqin Ma</dc:creator>
<dc:creator>Rui Zhao</dc:creator>
<dc:creator>Huai Yu</dc:creator>
<dc:creator>Tao Chen</dc:creator>
<dc:creator>Jinfeng Tan</dc:creator>
<dc:creator>Xiaohui Liu</dc:creator>
<dc:creator>Senqing Jiang</dc:creator>
<dc:creator>Jingbo Hou</dc:creator>
<dc:creator>Chao Fang</dc:creator>
<dc:creator>Gary S Mintz</dc:creator>
<dc:creator>Bo Yu</dc:creator>
<dc:date>2025-01-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Long-Term Prognostic Implications of Non-Culprit Lesions in Patients Presenting With an Acute Myocardial Infarction: Is It the Angiographic Stenosis Severity or the Underlying High-Risk Morphology?</dc:title>
<dc:identifier>pmid:39886764</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071855</dc:identifier>
</item>
<item>
<title>Remote Ischemic Conditioning Attenuates Transneuronal Degeneration and Promotes Stroke Recovery via CD36-Mediated Efferocytosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39886760/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250203213930&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: RIC induces a shift in monocytes to a proinflammatory state with elevated CD36 levels, and this is associated with CD36-dependent efferocytosis in Mφs that rescues delayed transneuronal degeneration in the postischemic brain and promotes stroke recovery. Together, these findings provide novel insight into our mechanistic understanding of how RIC improves poststroke recovery.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Jan 31. doi: 10.1161/CIRCRESAHA.124.325428. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Remote ischemic conditioning (RIC) has been implicated in cross-organ protection in cerebrovascular disease, including stroke. However, the lack of a consensus protocol and controversy over the clinical therapeutic outcomes of RIC suggest an inadequate mechanistic understanding of RIC. The current study identifies RIC-induced molecular and cellular events in the blood, which enhance long-term functional recovery in experimental cerebral ischemia.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Naive mice or mice subjected to transient ischemic stroke were randomly selected to receive sham conditioning or RIC in the hindlimb at 2 hours post-stroke. At 3 days post-stroke, monocyte composition in the blood was analyzed, and brain tissue was examined for monocyte-derived macrophage (Mφ), levels of efferocytosis, and CD36 expression. Mouse with a specific deletion of CD36 in monocytes/Mφs was used to establish the role of CD36 in RIC-mediated modulation of efferocytosis, transneuronal degeneration, and recovery following stroke.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: RIC applied 2 hours after stroke increased the entry of monocytes into the injured brain. In the postischemic brain, Mφ had increased levels of CD36 expression and efferocytosis. These changes in brain Mφ were derived from RIC-induced changes in circulating monocytes. In the blood, RIC increased CD36 expression in circulating monocytes and shifted monocytes to a proinflammatory LY6C<sup>High</sup> state. Conditional deletion of CD36 in Mφ abrogated the RIC-induced monocyte shift in the blood and efferocytosis in the brain. During the recovery phase of stroke, RIC rescued the loss of the volume and of tyrosine hydroxylase+ neurons in substantia nigra and behavioral deficits in wild-type mice but not in mice with a specific deletion of CD36 in monocytes/Mφs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: RIC induces a shift in monocytes to a proinflammatory state with elevated CD36 levels, and this is associated with CD36-dependent efferocytosis in Mφs that rescues delayed transneuronal degeneration in the postischemic brain and promotes stroke recovery. Together, these findings provide novel insight into our mechanistic understanding of how RIC improves poststroke recovery.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39886760/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250203213930&v=2.18.0.post9+e462414">39886760</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325428>10.1161/CIRCRESAHA.124.325428</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39886760</guid>
<pubDate>Fri, 31 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Hyunwoo Ju</dc:creator>
<dc:creator>Il-Doo Kim</dc:creator>
<dc:creator>Ina Pavlova</dc:creator>
<dc:creator>Shang Mu</dc:creator>
<dc:creator>Keun Woo Park</dc:creator>
<dc:creator>Joseph Minkler</dc:creator>
<dc:creator>Ahmed Madkoor</dc:creator>
<dc:creator>Wei Wang</dc:creator>
<dc:creator>Xiaoman Wang</dc:creator>
<dc:creator>Zhuhao Wu</dc:creator>
<dc:creator>Jiwon Yang</dc:creator>
<dc:creator>Maria Febbraio</dc:creator>
<dc:creator>John W Cave</dc:creator>
<dc:creator>Sunghee Cho</dc:creator>
<dc:date>2025-01-31</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Remote Ischemic Conditioning Attenuates Transneuronal Degeneration and Promotes Stroke Recovery via CD36-Mediated Efferocytosis</dc:title>
<dc:identifier>pmid:39886760</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325428</dc:identifier>
</item>





























</channel>
</rss>